A5061767014- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Ferroptosis and cancer prognosis
- RNA modifications and cancer
- Immune cells in cancer
- Epigenetics and DNA Methylation
- CAR-T cell therapy research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Single-cell and spatial transcriptomics
- Lung Cancer Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Mycobacterium research and diagnosis
- Bone Tumor Diagnosis and Treatments
- Asthma and respiratory diseases
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Shoulder and Clavicle Injuries
- Neuroinflammation and Neurodegeneration Mechanisms
- Multiple and Secondary Primary Cancers
- Chemokine receptors and signaling
The Netherlands Cancer Institute
2018-2024
Oncode Institute
2023-2024
University Hospital of Basel
2019
University of Oxford
2019
Slingeland Ziekenhuis
2015
The University of Texas MD Anderson Cancer Center
2013
Abstract Tumor mutation burden is an imperfect proxy of tumor foreignness and has therefore failed to consistently demonstrate clinical utility in predicting responses the context immunotherapy. We evaluated mutations regions genome that are unlikely undergo loss a pan-cancer analysis across 31 types ( n = 9,242) eight immunotherapy-treated cohorts patients with non-small-cell lung cancer, melanoma, mesothelioma, head neck cancer 524). discovered single-copy those present multiple copies per...
Immune checkpoint inhibitors have improved survival outcome of advanced non-small-cell lung cancer (NSCLC). However, most patients do not benefit. Therefore, biomarkers are needed that accurately predict response. We hypothesized molecular profiling exhaled air may capture the inflammatory milieu related to individual responsiveness anti-programmed death ligand 1 (PD-1) therapy. This study aimed determine accuracy breath analysis at baseline for assessing nonresponders versus responders...
Background Checkpoint inhibitors provided sustained clinical benefit to metastatic lung cancer patients. Nonetheless, prognostic markers in settings are still under research. Imaging offers distinctive advantages, providing whole-body information non-invasively, while routinely available most clinics. We hypothesized that more can be extracted by employing artificial intelligence (AI) for treatment monitoring, superior 2D tumor growth criteria. Methods A cohort of 152 stage-IV non-small-cell...
Durable clinical benefit to PD-1 blockade in non-small cell lung cancer (NSCLC) is currently limited a small fraction of patients, underlining the need for predictive biomarkers. We recently identified tumor-reactive tumor-infiltrating T lymphocyte (TIL) pool, termed PD-1T TILs, with potential NSCLC. Here, we examined TILs as biomarker NSCLC.PD-1T were digitally quantified 120 baseline samples from advanced NSCLC patients treated blockade. Primary outcome was disease control (DC) at 6...
The clinical value of STK11, KEAP1, and EGFR alterations for guiding immune checkpoint blockade (ICB) therapy in non-small cell lung cancer (NSCLC) remains controversial, as some patients with these proposed resistance biomarkers show durable ICB responses. More specific combinatorial biomarker approaches are urgently needed this disease.
Abstract Purpose: Although immunotherapy is the mainstay of therapy for advanced non–small cell lung cancer (NSCLC), robust biomarkers clinical response are lacking. The heterogeneity responses together with limited value radiographic assessments to timely and accurately predict therapeutic effect—especially in setting stable disease—calls development molecularly informed real-time minimally invasive approaches. In addition capturing tumor regression, liquid biopsies may be informative...
Immunotherapies, in particular immune checkpoint blockade (ICB), have improved the clinical outcome of cancer patients, although many fail to mount a durable response. Several resistance mechanisms been identified, but our understanding requirements for robust ICB response is incomplete. We engineered an MHC I/antigen: TCR-matched panel human NSCLC and T cells identify tumor cell-intrinsic cell mechanisms. The top differentially expressed gene resistant was SERPINB9. This serine protease...
Molecular profiling of tumours has become the mainstay diagnostics for metastasised solid malignancies and guides personalised treatment, especially in nonsmall cell lung cancer (NSCLC). In current practice, it is often challenging to obtain sufficient tumour material reliable molecular analysis. Cell-free DNA (cfDNA) blood or other bio-sources could present an alternative approach genetic information from tumour. a retrospective cohort we analysed added value cfDNA analysis pleural...
Abstract Purpose: Pretreatment selection of patients with non–small cell lung cancer (NSCLC) who would derive clinical benefit from treatment immune checkpoint inhibitors (CPIs) fulfill an unmet need by reducing unnecessary toxicities and result in substantial health care savings. Experimental Design: In a retrospective study, mass spectrometry (MS)-based proteomic analysis was performed on pretreatment sera derived advanced NSCLC treated nivolumab as part routine (n = 289). Machine learning...
Background The efficacy of PD-1 blocking agents in advanced NSCLC has shown prolonged effectiveness, but only a minority patients. Multiple biomarkers have been explored to predict treatment benefit, yet their combined performance remains inadequately examined. In this study, we assessed the predictive multiple patients treated with nivolumab. Methods Pretreatment samples from 135 receiving nivolumab were used evaluate CD8 tumor-infiltrating lymphocytes (TILs), intratumoral (IT) localization...
Because PD-1 blockade is only effective in a minority of patients with advanced-stage non-small cell lung cancer (NSCLC), biomarkers are needed to guide treatment decisions. Tumor infiltration by PD-1T tumor-infiltrating lymphocytes (TIL), dysfunctional TIL pool tumor-reactive capacity, can be detected digital quantitative IHC and has been established as novel predictive biomarker NSCLC. To facilitate translation this the clinic, we aimed develop robust RNA signature reflecting tumor's status.
<div>AbstractPurpose:<p>The clinical value of <i>STK11</i>, <i>KEAP1</i>, and <i>EGFR</i> alterations for guiding immune checkpoint blockade (ICB) therapy in non–small cell lung cancer (NSCLC) remains controversial, as some patients with these proposed resistance biomarkers show durable ICB responses. More specific combinatorial biomarker approaches are urgently needed this disease.</p>Experimental Design:<p>To develop a strategy...
Bony tumours of the chest wall are rare and radical surgical resection forms cornerstone treatment. Closure defect following can be challenging. We report case a 59-year-old woman with large tumour thoracic wall, which was surgically resected direct reconstruction using sandwich technique Palacos® patch placed in double-layer Marlex mesh. Pathological examination showed fibrous dysplasia rib. The patient had good functional cosmetic result.
Anti-PD-(L)1 immunotherapy has emerged as a promising treatment approach for non-small cell lung cancer (NSCLC), though the response rates remain low. Pre-treatment prediction may improve patient allocation immunotherapy. Blood platelets act active immune-like cells, thereby constraining T-cell activity, propagating metastasis, and adjusting their spliced mRNA content. We investigated whether platelet RNA profiles before start of nivolumab anti-PD1 predict responses. performed RNA-sequencing...